Danish allergy treatment company forms strategic US alliance  

ALK-Abelló and Schering-Plough join forces to develop tablet based alternative to injections

ALK-Abelló, a Danish company producing allergy treatments, has formed an alliance with the US Schering-Plough Corporation to conduct a clinical trial of tablet-based immunotherapy for the treatment of allergy symptoms caused by grass pollens. The agreement also contains a proviso for Schering-Plough to co-develop and co-promote the grass-pollen allergy tablet and all other non-injectable allergy products in ALK-Abelló’s research pipeline. The news is announced on ALK-Abelló's website.


For many years, gold standard allergy therapy has required ongoing injections, effectively excluding those who are averse to such treatments. The marketing potential of tablet based equivalents is plain to see – WHO estimates that up to 25 percent of the population in the US, Europe and Japan are afflicted by allergies. ALK-Abelló, headquartered north of Copenhagen, is wholly owned by Chr. Hansen Holding A/S, a company listed on the Copenhagen Stock Exchange (KFX). Schering-Plough is a NYSE listed company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×